Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRY005
MIFTS: 51

Cryptococcosis

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Cryptococcosis

About this section

MalaCards integrated aliases for Cryptococcosis:

Name: Cryptococcosis 12 75 53 59 55 44 15 17 33
Infection by Cryptococcus Neoformans 72
Cryptococcus Neoformans Infection 12
Busse-Buschke's Disease 12
European Cryptococcosis 12
Cryptococcal Infection 12
Torulosis 12
Torula 12

Characteristics:

Orphanet epidemiological data:

59
cryptococcosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12053
ICD9CM 35 117.5
MeSH 44 D003453
NCIt 50 C2967
SNOMED-CT 68 20850004 42386007
ICD10 33 B45 B45.9
MESH via Orphanet 45 D003453
ICD10 via Orphanet 34 B45.0 B45.1 B45.2 more
UMLS via Orphanet 73 C0010414
Orphanet 59 ORPHA1546
UMLS 72 C0010414
Sources

Summaries for Cryptococcosis

About this section
Disease Ontology : 12 An opportunistic mycosis that results in fungal infection and has material basis in Cryptococcus neoformans or Cryptococcus gattii.

MalaCards based summary : Cryptococcosis, also known as infection by cryptococcus neoformans, is related to cryptococcal meningitis and meningitis. An important gene associated with Cryptococcosis is SELL (Selectin L), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Amphotericin B and Lamivudine have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotype is hematopoietic system.

Wikipedia : 75 Cryptococcosis, is a potentially fatal fungal disease. It is caused by one of two species; Cryptococcus... more...

Sources

Related Diseases for Cryptococcosis

About this section

Diseases related to Cryptococcosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 473)
# Related Disease Score Top Affiliating Genes
1 cryptococcal meningitis 33.0 MBL2 IFNG
2 meningitis 31.3 MBL2 IFNG FCGR2A
3 candidiasis 30.9 PLB1 MBL2 IFNG
4 bacterial infectious disease 30.4 SELL MBL2 IFNG
5 folliculitis 30.1 IFNG FCGR3A
6 systemic lupus erythematosus 30.0 MBL2 IFNG FCGR3B FCGR3A FCGR2A
7 invasive aspergillosis 29.9 MBL2 IFNG
8 opportunistic mycosis 29.2 ST5 PLB1 IFNG CLEC6A
9 acquired immunodeficiency syndrome 10.7
10 human immunodeficiency virus type 1 10.7
11 fixed drug eruption 10.6 SELL IFNG
12 immune deficiency disease 10.6
13 meningoencephalitis 10.6
14 transient neonatal neutropenia 10.6 FCGR3B FCGR3A
15 aspergillosis 10.5
16 chronic graft versus host disease 10.5 IFNG CD4
17 cellulitis 10.4
18 lymphopenia 10.4
19 neisseria meningitidis infection 10.4 MBL2 FCGR2A
20 adult lymphoma 10.4 FCGR3A FCGR2A
21 hypersplenism 10.4 IFNG CD4
22 histoplasmosis 10.4
23 hydrocephalus 10.3
24 congenital hydrocephalus 10.3
25 poliomyelitis 10.3 IFNG FCGR3B FCGR3A
26 molluscum contagiosum 10.3
27 kawasaki disease 10.3 SELL MBL2 FCGR2A
28 primary thrombocytopenia 10.3 FCGR3A FCGR2A
29 behcet syndrome 10.3 SELL MBL2 IFNG
30 sarcoidosis 1 10.3
31 pulmonary tuberculosis 10.3
32 lupus erythematosus 10.3
33 common variable immunodeficiency 10.3 SELL MBL2 IFNG
34 liver cirrhosis 10.3
35 hypereosinophilic syndrome 10.3
36 kaposi sarcoma 10.2
37 lymphoma 10.2
38 respiratory failure 10.2
39 allergic hypersensitivity disease 10.2
40 headache 10.2
41 osteomyelitis 10.2
42 pneumocystosis 10.2
43 pneumonia 10.2
44 mucormycosis 10.2
45 intracranial hypertension 10.2
46 chronic meningitis 10.1
47 lymphocytic leukemia 10.1
48 nephrotic syndrome 10.1
49 lymphadenitis 10.1
50 peritonitis 10.1

Comorbidity relations with Cryptococcosis via Phenotypic Disease Network (PDN):


Acute Cystitis Cryptococcal Meningitis
Deficiency Anemia

Graphical network of the top 20 diseases related to Cryptococcosis:



Diseases related to Cryptococcosis
Sources

Symptoms & Phenotypes for Cryptococcosis

About this section

MGI Mouse Phenotypes related to Cryptococcosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.23 CD4 CD8A CLEC6A FCGR2A FCGR3B IFNG
Sources

Drugs & Therapeutics for Cryptococcosis

About this section

Drugs for Cryptococcosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
2
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
3
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
4
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
5
Zidovudine Approved Phase 4 30516-87-1 35370
6
Voriconazole Approved, Investigational Phase 4 137234-62-9 71616
7
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
10
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
11 Liposomal amphotericin B Phase 4
12 Antiparasitic Agents Phase 4
13 Anti-Bacterial Agents Phase 4
14 Antiprotozoal Agents Phase 4
15 Cytochrome P-450 CYP3A Inhibitors Phase 4
16 Cytochrome P-450 CYP3A Inducers Phase 4
17 Cytochrome P-450 Enzyme Inducers Phase 4
18 Reverse Transcriptase Inhibitors Phase 4
19 Nucleic Acid Synthesis Inhibitors Phase 4
20 Anti-HIV Agents Phase 4
21 Anti-Retroviral Agents Phase 4
22 Antiviral Agents Phase 4
23 Trace Elements Phase 4
24 Micronutrients Phase 4
25 Vitamin D2 Phase 4
26 Vitamins Phase 4
27 Ergocalciferols Phase 4
28 Nutrients Phase 4
29 Calciferol Phase 4
30 Calcium, Dietary Phase 4
31 Bone Density Conservation Agents Phase 4
32
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
33
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
34
Posaconazole Approved, Investigational, Vet_approved Phase 3 171228-49-2 147912
35
Isavuconazole Approved, Investigational Phase 3 241479-67-4
36
Sertraline Approved Phase 3 79617-96-2 68617
37 Pharmaceutical Solutions Phase 3
38
Hydroxyitraconazole Phase 3
39 Neurotransmitter Agents Phase 3
40 Serotonin Uptake Inhibitors Phase 3
41 Antidepressive Agents Phase 3
42 Neurotransmitter Uptake Inhibitors Phase 3
43 Serotonin Agents Phase 3
44 Psychotropic Drugs Phase 3
45
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
46
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
48
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
49
Flucytosine Approved, Investigational Phase 2 2022-85-7 3366
50 Antiemetics Phase 2

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV Completed NCT01656382 Phase 4 ABLC
2 Trial for the Optimal Timing of HIV Therapy After Cryptococcal Meningitis Completed NCT01075152 Phase 4 efavirenz
3 Operational Research for Cryptococcal Antigen Screening to Improve ART Survival Completed NCT01535469 Phase 4 Fluconazole
4 Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
5 An Open Label, Non-comparative, Multicenter Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infection Completed NCT00647907 Phase 4 Voriconazole
6 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis. Open Label Phase III Clinical Study Unknown status NCT01125644 Phase 3 SPK-843
7 Randomized Comparative Study of Fluconazole Versus Clotrimazole Troches in the Prevention of Serious Fungal Infection in Patients With AIDS or Advanced AIDS-Related Complex. (A Nested Study of ACTG 081) Completed NCT00000676 Phase 3 Clotrimazole;Fluconazole
8 A Pharmacokinetic Study of JK1211 in Patients With Systemic Fungal Infection (SFI) and Patients With Febrile Neutropenia (FN) Suspected of Fungal Infection. Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
9 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034658 Phase 3 Posaconazole
10 Open Label, Treatment Protocol for the Safety and Efficacy of Posaconazole (SCH 56592) in the Treatment of Invasive Fungal Infections Completed NCT00034632 Phase 3 Posaconazole oral suspension
11 Comparison of Fluconazole (UK-49,858) and Amphotericin B for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00001017 Phase 3 Fluconazole;Amphotericin B
12 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
13 Cryptococcal Antigen Screening Plus Sertraline Terminated NCT03002012 Phase 3 Sertraline;Placebo Oral Tablet;Fluconazole
14 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
15 Dexamethasone in Cryptococcal Meningitis Completed NCT00000776 Phase 2 Flucytosine;Fluconazole;Amphotericin B;Dexamethasone
16 An Open Label Randomized Controlled Phase IIb Trial to Determine the Safety of Oral Fluconazole in Combination With Flucytosine as Compared to Fluconazole Alone Terminated NCT01562132 Phase 2 Flucytosine and fluconazole;Fluconazole
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Mycograb® as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS Terminated NCT00324025 Phase 2 Mycograb;placebo
18 A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection Withdrawn NCT03196921 Phase 1, Phase 2 Encochleated Amphotericin B
19 SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy Completed NCT00000677 Phase 1 SCH 39304
20 Multi-center Clinical Trial of Pulmonary Cryptococcosis in China Unknown status NCT02503449
21 Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection Completed NCT00001701
22 Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia Completed NCT02113930
23 Special Investigation Of Fluconazole For Pediatric Subjects Completed NCT01680458 Fluconazole
24 Pilot Study of Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002076 Fluconazole
25 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002305 Flucytosine;Fluconazole;Amphotericin B
26 Double Blind Placebo Controlled Study of Fluconazole (UK-49,858) for Maintenance Treatment of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002294 Fluconazole
27 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002075 Flucytosine;Fluconazole;Amphotericin B
28 Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome Completed NCT00002074 Fluconazole;Amphotericin B
29 A Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00002068 Fluconazole;Amphotericin B
30 Randomized Study Comparing Itraconazole to Placebo in the Prevention of Histoplasmosis in Patients With Human Immunodeficiency Virus Infection Completed NCT00002438 Itraconazole
31 Multi-Center Evaluation of Fluconazole (UK-49,858) as Treatment for Acute Cryptococcal Meningitis in Patients Who Have Failed to Respond or Have Experienced Unacceptable Toxicity During Treatment With Amphotericin B Completed NCT00002306 Fluconazole
32 An Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002077 Fluconazole
33 Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00002040 Fluconazole
34 Safety and Efficacy of Amphotericin B Lipid Complex in the Treatment of Cryptococcal Meningitis in Patients With the Acquired Immunodeficiency Syndrome Completed NCT00002019 Amphotericin B, Lipid-based;Amphotericin B
35 Randomized Control Trial of Early vs Delayed ART in the Treatment of Cryptococcal Meningitis. Completed NCT00830856 Fluconazole;Fixed dose - Stavudine, lamivudine and Nevirapine;Fixed dose - Stavudine, Lamivudine, Nevirapine
36 Plasma Nevirapine Levels and Adverse Events Among HIV-Infected Patients Concurrently Receiving Nevirapine-Based Antiretroviral Therapy and Fluconazole Completed NCT00309582
37 A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis. Completed NCT00002113 Flucytosine;Fluconazole
38 A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis Completed NCT00000639 Itraconazole;Flucytosine;Fluconazole;Amphotericin B
39 A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients With CD4 Count Less Than or Equal to 100 Cells/microL Who Are Initiating Antiretroviral Therapy Completed NCT00286767
40 Multi-center Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis Completed NCT00000708 Flucytosine;Fluconazole;Amphotericin B
41 AIDS-Associated Heart Disease -- Incidence and Etiology Completed NCT00005228
42 Cryptococcosis in Previously Healthy Adults Recruiting NCT00001352
43 AIDS Defining Opportunistic Infections in Naive HIV Cases Recruiting NCT03993093
44 Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models Recruiting NCT02015013
45 Vicente Ferrer HIV Cohort Study Recruiting NCT02454569
46 Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1 Active, not recruiting NCT03267407
47 Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia Not yet recruiting NCT04033120

Search NIH Clinical Center for Cryptococcosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Flucytosine
Itraconazole

Cochrane evidence based reviews: cryptococcosis

Sources

Genetic Tests for Cryptococcosis

About this section
Sources

Anatomical Context for Cryptococcosis

About this section

MalaCards organs/tissues related to Cryptococcosis:

41
Lung, Testes, Liver, Skin, Brain, Bone, T Cells
Sources

Publications for Cryptococcosis

About this section

Articles related to Cryptococcosis:

(show top 50) (show all 4870)
# Title Authors PMID Year
1
Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. 9 38
15776384 2005
2
Basic principles of the virulence of Cryptococcus. 38
31119976 2019
3
Cryptococcosis in the Amazon: A current overview and future perspectives. 38
31181189 2019
4
Isolation of Cryptococcus gattii from feline chronic stage lipoid pneumonia. 38
31249771 2019
5
Mortality After Cryptococcal Infection in the Modern Antiretroviral Therapy Era. 38
31408451 2019
6
The regulation of the sulfur amino acid biosynthetic pathway in Cryptococcus neoformans: the relationship of Cys3, Calcineurin, and Gpp2 phosphatases. 38
31417135 2019
7
Hemophagocytic lymphohistiocytosis: a rare association with pulmonary cryptococcosis. 38
31401574 2019
8
Discovery of Simplified Sampangine Derivatives with Potent Antifungal Activities against Cryptococcal Meningitis. 38
31070884 2019
9
Central Nervous System Cryptococcal Infections in Non-HIV Infected Patients. 38
31382367 2019
10
Did This Cryptococcosis Patient Have HIV Coinfection? 38
31391390 2019
11
Are Macrophages the Heroes or Villains During Cryptococcosis? 38
31415906 2019
12
The Authors' Reply to "Did This Cryptococcosis Patient Have HIV Coinfection?" 38
31391397 2019
13
Antifungal activity of Annona coriacea Mart. ethanol extracts against the aetiological agents of cryptococcosis. 38
29463129 2019
14
Right Lung Consolidation Combined Elevated Serum Neuron Specific Enolase Misdiagnosed as Lung Carcinoma Ultimately Confirmed Pulmonary Cryptococcosis by CT-guided Percutaneous Lung Biopsy: a Case Report and Literature Review. 38
31414753 2019
15
Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model. 38
31420668 2019
16
Candida species isolated from pigeon (Columbia livia) droppings may express virulence factors and resistance to azoles. 38
31282378 2019
17
The enigmatic role of fungal annexins: the case of Cryptococcus neoformans. 38
31140968 2019
18
Pleural fluid secondary to pulmonary cryptococcal infection: a case report and review of the literature. 38
31405376 2019
19
[Fungal infections]. 38
31119309 2019
20
Identification of Cryptococcus antigen in human immunodeficiency virus-positive Turkish patients by using the Dynamiker® lateral flow assay. 38
31344286 2019
21
A Case of Intramuscular Cryptococcosis Mimicking a Malignant Tumor on FDG PET/CT. 38
30762821 2019
22
An unusual presentation of primary cutaneous cryptococcosis. 38
31012217 2019
23
Cryptococcus neoformans infection in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected patients at an inner-city tertiary care hospital in the Bronx. 38
31342058 2019
24
Cryptococcal pleuritis with pleural effusion as the only clinical presentation in a patient with hepatic cirrhosis: A case report and literature review. 38
31305427 2019
25
Pioglitazone as an adjuvant of amphotericin B for the treatment of cryptococcosis. 38
31279153 2019
26
Diagnosis and Management of Central Nervous System Cryptococcal Infections in HIV-Infected Adults. 38
31330959 2019
27
Mortality by cryptococcosis in Brazil from 2000 to 2012: A descriptive epidemiological study. 38
31356603 2019
28
Diagnosis of Pulmonary Cryptococcosis by EBUS-TBNA in a Healthy Young Man. 38
31233474 2019
29
Pulmonary cryptococcosis characteristics in immunocompetent patients-A 20-year clinical retrospective analysis in China. 38
31287920 2019
30
Disseminated cryptococcosis with granuloma formation in idiopathic CD4 lymphocytopenia. 38
31345742 2019
31
[Dynamic research of serum cryptococcal capsular polysaccharide antigen titer and chest CT of pulmonary cryptococcosis after antifungal therapy]. 38
31315373 2019
32
Unveil the transcriptional landscape at the Cryptococcus-host axis in mice and nonhuman primates. 38
31329596 2019
33
Cryptococcus neoformans pericarditis in a lung transplant recipient: Case report, literature review and pearls. 38
31267603 2019
34
Repurposing the thrombopoietin receptor agonist eltrombopag as an anticryptococcal agent. 38
31297540 2019
35
Cryptococcus neoformans resists to drastic conditions by switching to viable but non-culturable cell phenotype. 38
31356623 2019
36
Rheological properties of cryptococcal polysaccharide change with fiber size, antibody binding and temperature. 38
31340660 2019
37
Fulminant myocardial cryptococcosis in an human immunodeficiency virus infected patient. 38
30502306 2019
38
Placental and pulmonary cryptococcosis associated with fungemia in patient with acquired immunodeficiency syndrome. 38
31205044 2019
39
Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study. 38
31242860 2019
40
Clinical Characteristics and Etiologies of Miliary Nodules in the US: A Single-Center Study. 38
30659816 2019
41
Risk factors of laryngeal cryptococcosis: A case report. 38
31080714 2019
42
Cryptococcal-related mortality despite fluconazole pre-emptive treatment in a cryptococcal antigen (CrAg) screen-and-treat programme. 38
31179488 2019
43
A Mimic of Hepatic Encephalopathy: Two Cases of Cryptococcal Meningitis in North America. 38
31293920 2019
44
Factors Associated With Ventriculoperitoneal Shunt Placement in Patients With Cryptococcal Meningitis. 38
31214629 2019
45
In vitro combination between antifungals and diphenyl diselenide against Cryptococcus species. 38
30776159 2019
46
Antibody immunity and natural resistance to cryptococcosis. 38
31134140 2019
47
Infectious particle identity determines dissemination and disease outcome for the inhaled human fungal pathogen Cryptococcus. 38
31247052 2019
48
Successful treatment with voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation. 38
31161376 2019
49
Cryptococcosis due to Cryptococcus gattii VGII in southeast Brazil: The One Health approach revealing a possible role for domestic cats. 38
31061785 2019
50
Mediastinal cryptococcosis simulating thyroid neoplasia in immunocompetent patient with prior diagnosis and treatment for COPD. 38
31080717 2019
Sources

Variations for Cryptococcosis

About this section
Sources

Expression for Cryptococcosis

About this section
Search GEO for disease gene expression data for Cryptococcosis.
Sources

Pathways for Cryptococcosis

About this section

Pathways related to Cryptococcosis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.78 SELL MBL2 IFNG FCGR3B FCGR3A FCGR2A
2
Toxoplasmosis 37
Show member pathways
 12.03 IFNG FCGR3B FCGR3A FCGR2A
3
Tuberculosis 37
11.99 IFNG FCGR3B FCGR3A FCGR2A
4
Phagosome 37
11.89 MBL2 FCGR3B FCGR3A FCGR2A
5
Cell adhesion molecules (CAMs) 37
11.86 SELL CD8A CD4
6
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
11.82 SELL FCGR3A CD8A
7
Osteoclast differentiation 37
11.78 IFNG FCGR3B FCGR3A FCGR2A
8
IL12-mediated signaling events 1
Show member pathways
 11.72 IFNG CD8A CD4
9
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.72 IFNG FCGR3B FCGR3A FCGR2A
10
Innate Lymphoid Cell Differentiation Pathways 65
11.56 IFNG CD8A CD4
11
Dendritic Cells Developmental Lineage Pathway 65
11.43 SELL IFNG CD8A CD4
12
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.31 IFNG FCGR3B FCGR3A FCGR2A
13
Staphylococcus aureus infection 37
11.24 MBL2 FCGR3B FCGR3A FCGR2A
14
Primary immunodeficiency 37
11.14 CD8A CD4
15
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.09 SELL IFNG FCGR2A CD8A CD4
16
Cytokines and Inflammatory Response 1
11.02 IFNG CD4
17
IL12 signaling mediated by STAT4 1
10.99 IFNG CD4
Sources

GO Terms for Cryptococcosis

About this section

Cellular components related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.46 SELL FCGR3A CD8A CD4
2 T cell receptor complex GO:0042101 8.96 CD8A CD4
3 secretory granule membrane GO:0030667 8.8 SELL FCGR3B FCGR2A

Biological processes related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.13 SELL FCGR3A CD8A
2 immune response GO:0006955 9.02 IFNG FCGR3B FCGR3A CD8A CD4

Molecular functions related to Cryptococcosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.43 SELL MBL2 CLEC6A
2 coreceptor activity GO:0015026 9.16 CD8A CD4
3 mannose binding GO:0005537 8.96 MBL2 CLEC6A
4 IgG binding GO:0019864 8.8 FCGR3B FCGR3A FCGR2A
Sources

Sources for Cryptococcosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....